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ABSTRACT
Introduction Currently, we are unable to accurately 
predict mortality or neurological morbidity following 
resuscitation after paediatric out of hospital (OHCA) or 
in- hospital (IHCA) cardiac arrest. A clinical prediction 
model may improve communication with parents and 
families and risk stratification of patients for appropriate 
postcardiac arrest care. This study aims to the derive and 
validate a clinical prediction model to predict, within 1 hour 
of admission to the paediatric intensive care unit (PICU), 
neurodevelopmental outcome at 3 months after paediatric 
cardiac arrest.
Methods and analysis A prospective study of children 
(age: >24 hours and <16 years), admitted to 1 of the 24 
participating PICUs in the UK and Ireland, following an 
OHCA or IHCA. Patients are included if requiring more than 
1 min of cardiopulmonary resuscitation and mechanical 
ventilation at PICU admission Children who had cardiac 
arrests in PICU or neonatal intensive care unit will be 
excluded. Candidate variables will be identified from data 
submitted to the Paediatric Intensive Care Audit Network 
registry. Primary outcome is neurodevelopmental status, 
assessed at 3 months by telephone interview using the 
Vineland Adaptive Behavioural Score II questionnaire. A 
clinical prediction model will be derived using logistic 
regression with model performance and accuracy 
assessment. External validation will be performed using 
the Therapeutic Hypothermia After Paediatric Cardiac 
Arrest trial dataset. We aim to identify 370 patients, 
with successful consent and follow- up of 150 patients. 
Patient inclusion started 1 January 2018 and inclusion will 
continue over 18 months.
Ethics and dissemination Ethical review of this protocol 
was completed by 27 September 2017 at the Wales 
Research Ethics Committee 5, 17/WA/0306. The results of 
this study will be published in peer- reviewed journals and 
presented in conferences.
Trial registration number NCT03574025.
INTRODUCTION
Paediatric cardiac arrest
Paediatric cardiac arrest (CA) is an 
uncommon but potentially catastrophic event 
for both children and their families. CA is 
defined as the cessation of cardiac mechan-
ical activity occurring with absence of signs 
of circulation. Approximately 1500 infants 
or children per year suffer a CA in the UK 
and Ireland (RoI) with between 250 and 350 
admitted to a paediatric intensive care unit 
(PICU) for postresuscitation care.1 Survival 
to PICU discharge for this population is 
Strengths and limitations of this study
 ► This protocol has followed the international rec-
ommended Transparent Reporting of a multivari-
able prediction model for Individual Prognosis or 
Diagnosis guidelines for the derivation and valida-
tion of a clinical prediction model of neurodevelop-
mental outcome after paediatric cardiac arrest.
 ► A nationwide study which will efficiently combine 
routinely collected data through the existing, high- 
quality, Paediatric Intensive Care Audit Network da-
tabase and a bespoke research database.
 ► Personalised recruitment and local follow- up will 
aim to maximise participant retention.
 ► The low incidence and wide variety of causes of 
paediatric cardiac arrest may restrict number of 
available patients and are potential limitations in 
prospective prognostic research in this population.
 ► Baseline neurodevelopmental status of patients will 
only be allocated retrospectively using the Paediatric 
Cerebral Performance Category tool.
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achieved in 35%–45% patients admitted to PICU after an 
out of hospital CA (OHCA) and 45%–55% after in- hos-
pital CA (IHCA). However, 50% of survivors are estimated 
to have ongoing neurodevelopmental disabilities despite 
advances in post- CA management.2 3 The high mortality 
and morbidity rates are often associated with the degree 
of brain injury from the hypoxic- ischaemic insult at the 
time of CA.
Prognostication after CA
Clinicians are currently unable to accurately predict 
survival with a good neurodevelopmental outcome after 
CA with any certainty due to a lack of data.4–6 Clinicians 
can be pessimistic, optimistic or unnecessarily ambiguous 
in their predictions, and this affects the clarity of commu-
nication with families and the implementation of ongoing 
treatment plans.4 Improved prognostication is, therefore, 
a high priority for parents of children who have suffered 
a CA. In addition, early stratification of patients who may 
benefit from critical care interventions would also be a 
significant advancement in their treatment7 8 and has 
been lacking in major studies to date.2 3
Several prognostic factors are associated with survival 
following paediatric CA, such as patient age and pre- 
existing comorbidities,9 CA characteristics (location, 
initial CA rhythm, duration of CA, presence and actions 
of bystanders,9 10 physiological observations (eg, pupil-
lary response, blood lactate, systolic blood pressure)1 10 11 
and specific medical interventions.11 12 However, studies 
examining prognostic factors for good neurodevelop-
mental outcome are much less frequent.
The importance and weighting of these factors in prog-
nosis decision making is complex and in 2010 the Inter-
national Liaison Committee On Resuscitation (ILCOR) 
consensus statement identified a significant gap in knowl-
edge in prognostic modelling with children5 with no addi-
tional ‘high- quality’ data to inform the 2015 guidance.13
Rationale for study
Accurate early prediction of neurodevelopmental 
outcomes may reduce uncertainty and improve commu-
nication with families. It may also provide better risk strat-
ification for clinical trials and individualised treatment 
of patients. Furthermore, we aim to gain a better under-
standing of the epidemiology and neurodevelopmental 
outcomes of children after CA in the UK and RoI.
METHODS AND ANALYSIS
Study aims
The aim of the NEUROlogical Prognosis After Cardiac 
Arrest in Kids study is to (1) derive a clinical prediction 
model using key factors prospectively collected from a 
cohort of patients, available within the first hour of PICU 
admission after paediatric CA to predict good neurode-
velopmental outcome at 3 months, (2) externally validate 
the clinical prediction model using an existing paediatric 
CA dataset and (3) describe the current epidemiology of 
CA cases in the UK and Ireland (RoI).
Study design
This study is a multicentre, nationwide, prospective obser-
vational study combining both registry and cohort data. 
See figure 1 for study overview.
Setting
Patients will be enrolled from 24 PICUs within the UK and 
RoI. All study sites admit infants and children following 
CA and routinely submit audit data to the Paediatric 
Intensive Care Audit Network (PICANet) registry.
Ongoing PICU registry: PICANet and NET-PACK 3
Since 2002, PICANet has prospectively collected demo-
graphic, diagnostic, and interventional data along with 
PICU survival outcomes for patients admitted to PICUs 
in England and Wales and now collects data for patients 
across the UK and RoI.14 This includes severity of illness 
variables to build the Paediatric Index of Mortality (PIM) 
risk- adjustment models.15
PICANet is also conducting an ongoing customised 
data collection of post- CA management: PICANet Post 
Arrest Care in Kids (NET- PACK 3) with data definition 
and data collection form (online supplemental mate-
rials 1 and 2). NET- PACK 3 customised data collection 
includes resuscitation variables available within a few 
hours of the CA. Data are either collected within 1 hour 
of admission onto PICU or within 1 hour of the atten-
dance at the patient’s bedside of a specialist paediatric 
critical care team (eg, a specialised retrieval team travels 
to another hospital without a PICU). These variables 
include: (1) attempted bystander cardiopulmonary resus-
citation (CPR), (2) duration of CPR, (3) requirement of 
CPR after arrival at emergency department, (4) number 
Figure 1 NEUROPACK study overview: population, data 
collection tools and primary outcome. CPR, cardiopulmonary 
resuscitation; IHCA, in- hospital cardiac arrest; NEUROPACK, 
NEUROlogical Prognosis After Cardiac Arrest in Kids; OHCA, 
out of hospital cardiac arrest; PICU, paediatric intensive 
care unit; PlCANET, Paediatric Intensive Care Audit Network; 
NETPACK 3, PICANet Post Arrest Care in Kids audit; VABS II, 
Vineland Adaptive Behavioural Score 2nd ed.
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of doses of epinephrine (epinephrine) required and (5) 
initial presenting cardiac rhythm. These factors were 
chosen to comply with Utstein style CA reporting guide-
lines.16 17 PICANet collects survival to PICU discharge 
outcome data for all admissions.
ELIGIBILITY FOR NEUROLOGICAL PROGNOSIS AFTER CARDIAC 
ARREST IN KIDS
Inclusion
All patients aged 24 hours up to 16th birthday admitted 
to PICU after OHCA or IHCA will be included. CA will 
be defined as requiring >1 min CPR. Patients will be 
included if they require invasive (eg, via endotracheal or 
tracheostomy) mechanical ventilation at PICU admission.
Exclusion
Exclusion criteria include CAs occurring within a PICU or 
neonatal intensive care unit. For children who survive to 
PICU discharge we will exclude patients where the local 
clinical team at participating sites feel inclusion is inap-
propriate and/or parent/guardian or family member of 
children are unable to understand the telephone ques-
tionnaires for neurodevelopmental outcome assessments 
in English. All patients under the age of 24 hours will be 
excluded due to potentially different aetiology of CA 
related to birth events.
Identification and screening
Patients for the NEUROlogical Prognosis After Cardiac 
Arrest in Kids (NEUROPACK) study will be identified via 
entry into the PICANet database and by local researchers 
at each site screening PICU admissions daily. ‘CA 
preceding ICU admission—out of hospital or in- hospital’ 
is a specific high risk category in the PIM-3 risk adjustment 
model and is recorded within 1 hour of PICU admission, 
or within 1 hour of the attendance at the patient’s bedside 
of a specialist paediatric critical care team.15
Recruitment for neurodevelopmental outcome assessment
Parent/guardians of CA patients who are expected to 
survive to 3 months following CA will be approached by 
local research staff, trained in Good Clinical Practice, to 
consent for telephone questionnaire at 3 months post- CA.
This is a very sensitive and difficult time for parents and 
guardians. The approach to parents or guardians of crit-
ical ill children for recruitment to the NEUROPACK study 
will, therefore, be handled sensitively. Local researchers 
will be trained to identify the appropriate time to consent, 
use passive information giving to reduce burden of infor-
mation (eg, Ethics committee- approved posters displayed 
in family rooms) and liaise with the medical team 
managing the patient to acknowledge ongoing clinical 
management issues. Local site investigator (or delegate) 
will recontact parents or guardians at 2 months following 
CA to ascertain continued involvement in the study and 
to confirm ongoing contact details.
Potential predictive factors collected
Potential candidate variables for the NEUROPACK clin-
ical prediction model have been selected from the existing 
clinical prediction models for survival.1 6 13 Final candi-
date variable selection will follow assessment of statistical 
modelling interaction and practicality of collecting vari-
ables in a timely fashion at the bedside by clinicians.
Data collections
The ongoing NET- PACK 3 customised data collection and 
PICANet data collection for the PIM3 risk of mortality will 
be the data source for all the candidate variables in the 
NEUROPACK study. Linkage of individual patient NET- 
PACK 3 data with the collected neurodevelopmental 
outcome will be carried out for consented patients only. 
Pseudonymised data from NET- PACK 3 customised data 
collection and PICANET will be used for patients who 
die or for patients who survive and consent for follow- up 
assessment is not available.
PRIMARY AND SECONDARY OUTCOMES
Primary outcome
The primary outcome is survival with a good neurodevel-
opmental outcome at 3 months postevent. Good neurode-
velopmental outcome is defined as a Vineland Adaptive 
Behaviour Scales second edition (VABS- II) score of ≥70.18
Primary outcome assessment
The VABS- II was designed as a caregiver report measure 
to assess communication, daily living, social and motor 
domains of adaptive behaviour.18 This tool can be used 
across the entire paediatric age range (0–16 years) and 
requires a short interview which can be via telephone. 
VABS- II is sensitive to neurological injury and has been 
used successfully in paediatric neurocritical care studies.2 
VABS- II has a normal mean value score of 100 (SD of 15). 
Good neurodevelopmental outcome is defined as a score 
of ≥70. Poor outcome is a composite score of VABS- II 
<70 and death. The chief investigator or the lead research 
nurse at the Central Research Centre (Birmingham 
Women and Children’s National Health Service (NHS) 
Foundation Trust, UK) will conduct all assessments. At 
the time of outcome assessment, the assessor will remain 
blinded to the clinical prediction model and component 
variables.
Secondary outcomes
Paediatric cerebral performance category (PCPC) and 
paediatric overall performance category (POPC) at 
3 months and change in PCPC and POPC score from base-
line.19 Survival to PICU discharge and 3 months post- CA.
Secondary outcome assessment
PCPC and POPC scale can be calculated by a short ques-
tionnaire conducted at the 3- month follow- up interview 
for consented patients. A baseline (pre- CA) PCPC and 
POPC will also retrospectively ascertained at the 3- month 
follow- up. PCPC and POPC have been recommended for 
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reporting in all paediatric CA studies. They score 1–6 (1: 
normal, 2: mild disability, 3: moderate disability, 4: severe 
disability, 5: vegetative state or coma and 6: death). They 
provide less detail but correlate reasonably well with VABS 
II.20 This will allow comparison with other CA studies. 
Good neurodevelopmental outcome will be defined as 
PCPC score of 1–3 or no change from baseline. Poor 
outcome will be defined as a score of 4 or more, including 
death. Three months follow- up time point is chosen 
following the ILCOR, core outcome set for adults after 
CA recommendation21 and demonstration of minimal 
change between three and 12- month following CA.22
STATISTICAL CONSIDERATION
Data analysis plan
The data will be manually reviewed for errors, missing 
data and outliers before analysis. Extreme values will 
be set to missing if they are deemed unlikely, based on 
their validity range. Descriptive analysis of the data will be 
reported. Continuous variables will be reported as either 
median and interquartile range (IQR) or mean and stan-
dard deviation (SD) based on the distribution. Categor-
ical variables will be described in numbers, percentages 
or both.
Sample size
To reduce problematic bias and improve precision we aim 
for at least 10 events per variable considered for multi-
variable modelling.23 Following pilot data collection, we 
calculate 250 CA patients per year are admitted to 27 UK 
and RoI PICUs, 125 (50%) will survive to PICU discharge 
and 70 (30%) per year will survive with good neuro- 
developmental outcome. To test seven variables we esti-
mate a requirement of 70 events (eg, patients with good 
neurodevelopmental outcome). One hundred per cent of 
non- survivors will be included (included in PICANet and 
NET- PACK 3 audit database). We anticipate 80% recruit-
ment and consent rate of remaining survivors. We, there-
fore, require data collection over an 18- month period to 
recruit 370 patients. We anticipate that this would ensure 
successful consent and follow- up of 150 patients, of whom 
75 patients are estimated to have a good neurodevelop-
mental outcome.
Statistical methods for developing a prognostic model
We will develop a prognostic model using logistic regres-
sion analysis of candidate variables and a good neurode-
velopmental outcome as the primary outcome variable. 
Multiple imputation (using chained equations) will be 
used for any variables with missing data considered in the 
model. Auxiliary variables will be used to aid the imputa-
tion. The number of imputed data sets used will be equal 
to the fraction of missing data.24
Box 1 lists all candidate variables. Those variables 
deemed to be clinically important will be forced into 
the final model. Candidate variables will be retained if 
they benefit the model. The process will begin by fitting 
the full model and then performing backwards elimina-
tion, with a conservative significance level of 0.157.25 For 
categorical variables, the category with the lowest p value 
will dictate whether the variable is included in the final 
model.
All continuous variables will be left in their raw form 
to ensure no data were lost through dichotomisation or 
categorisation. It will be initially assumed that variables 
follow a linear trend, before fractional polynomials 
will be considered using the following powers: -2, –1, 
−0.5, natural logarithm, 0.5, 1, 2, and 3. A p<0.001 will 
be required to use a fractional polynomial rather than 
assuming a linear trend.26 The use of fractional polyno-
mials will also be considered for all continuous variables 
eliminated from the model to check whether this changes 
their inclusion status.
Assessment of prognostic model performance
Assessment of the fitted model will be achieved by esti-
mating calibration and discrimination. A calibration plot 
will be produced by plotting the observed risk against 
the predicted risk and the calibration slope calculated. 
We expect the slope should be approximately one as 
the model developed will be developed using this data. 
Box 1 Patient and cardiac arrest characteristics
Patient Demographic
 ► Age in years.*
 ► Presence of PIM-3 ‘high- risk’ comorbidities.†15
Cardiac arrest characteristics and interventions
 ► Location of cardiac arrest (IH & OHCA).†
OHCA is assigned if chest compressions were initiated before hos-
pital arrival.
 ► Aetiology of arrest (cardiac and non- cardiac).†
 ► Duration of cardiopulmonary resuscitation.*
 ► Continuation of cardiopulmonary resuscitation after Emergency 
Department arrival (for OHCA only).†.
 ► Bystander cardiopulmonary resuscitation.†
 ► Initial cardiac rhythm recorded during CA (shockable and 
non- shockable).†
 ► Doses of epinephrine (epinephrine) during cardiopulmonary 
resuscitation.*
 ► Use of continuous vasoactive infusions within 1 hour of PICU 
admission.†
Service characteristics
 ► Requirement of inter- hospital transfer prior to PICU admission.†
 ► Time of arrest day (07:00–18:59) or night (19:00–06:59).†
Physiological variables
Measured for PIM-3 calculation: within 1 hour of PICU admission or 
within 1 hour of the attendance at the patient’s bedside of a specialist 
paediatric critical care team
 ► Systolic blood pressure.*
 ► Pupillary reaction to light (greater than 3 mm and both fixed and 
other).†
 ► Blood lactate level.*
*continuous data, †categorical data.
IH, in- hospital; OHCA, out- of- hospital cardiac arrest; PIM-3, Paediatric Index of 
Mortality 3 score.
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To judge discrimination, the area under the receiver 
operating curve (equivalent to the C- statistic) and the R 
squared statistic will be calculated.
Internal validation of the prognostic model
The model will be internally validated using bootstrap 
methods. The original data will be used to generate 100 
bootstrapped data sets. Each one of these bootstrapped 
data sets will then be used to develop a prognostic model 
in the same way as the original model. Estimates of perfor-
mance (C- statistic and calibration slope) will be obtained 
from the model fitted using each of the bootstrapped 
data sets. The estimates obtained from the bootstrapped 
data sets will be averaged and subtracted from the esti-
mates from the original model to estimate optimism and 
provide optimism- adjusted performance statistics.
Final prognostic model
The optimised adjusted calibration slope will then be 
used as a uniform shrinkage factor. Each of the coeffi-
cients from the original model will be adjusted for by 
multiplying by the shrinkage factor. The intercept will 
also be adjusted to ensure calibration- in- the- large, the 
average predicted probability, is the same as the average 
observed probability.
Secondary analysis
Using the secondary outcomes, we will repeat the steps 
above to create a supplemental final prognostic model, 
for survival to PICU and survival to 3 months. In addition, 
we will create a prognostic model for good neurodevelop-
mental outcome using POPC and PCPC outcome scores.
There is a potential for survivors to decline consent, be 
lost to follow- up, or fulfil the exclusion criteria into the 
NEUROPACK study, and therefore, there is a risk that the 
survival subgroup may be biased. We plan to undertake 
sensitivity analyses by (1) imputing missing VABS II score 
for survivors using their known PICANet and NETPACK 
3 data, (2) assume all survivors without a neurodevelop-
mental score had a VABS II score ≥70 and (3) assume 
all survivors without a neurodevelopmental score had a 
VABS II score <70, to ascertain impact of this group on 
the final prognostic model.
In addition, due to the limitations of not having a 
baseline VABS II score, we will also perform a secondary 
analysis using VABS II score ≥70 as the good neurode-
velopmental outcome for a subgroup of patients with a 
known baseline PCPC score 1–3. This will allow compar-
ison of the final prognostic model for all patients and the 
subgroup with known good neurodevelopment outcome 
at baseline.
External validation of the NEUROPACK prognostic score
As part of the process of ensuring a prediction model is 
considered clinically useful, it must be validated in an 
external dataset.27 We aim to do this by validating the 
NEUROPACK prognostic model in the publically acces-
sible dataset for the Therapeutic Hypothermia After 
Paediatric Cardiac Arrest OHCA and IHCA randomised 
controlled trials in the National Institute for Health 
Biolincc repository (Http:// biolincc. nhlbi. nih. gov).2 3 
The sample size of the dataset to be used for external vali-
dation should be sufficient to provide reliable and accu-
rate results. To externally validate the model, predictions 
of risk for each patient in the external validation dataset 
are made, and performance statistics, such as the C- sta-
tistic, are calculated in the same manner as described 
earlier.
PATIENT AND PUBLIC INVOLVEMENT
Given the sensitive and emotive nature of the 
NEUROPACK study, and the need for active parent 
and family engagement throughout, a patient advisory 
group, consisting of parents with experience of critical 
illness and death in children, and the Clinical Research 
Network: Children young person’s advisory group (a sub 
group of the Generation R group aged 9–17 years) have 
been consulted in designing the protocol, the informa-
tional material to support the intervention, and to under-
stand the burden of the intervention from the patient’s 
perspective. At the end of the study, the patient advisory 
group will be consulted on findings and contribute to the 
dissemination plan.
ETHICS AND DISSEMINATION
PICANet has ethical approval as a research database 
granted by the East Midlands, Derby Research Ethics 
Committee (ref 18/EM/0267) and NHS Health Research 
Authority Confidentiality Advisory Group approval (ref 
PIAG 4–07/(c)2002) to collect personally identifiable 
data without consent. The PICANet Clinical Advisory 
Group has approved pseudonymised sharing of PICANet 
audit data for the NEUROPACK study and Data Sharing 
Agreements will be established with the data controllers 
for the PICANet dataset prior to the release of de- identi-
fied PICANet and NET- PACK 3 data. Quality control of 
NET- PACK 3 customised data collection, data definitions 
and data collection is performed by the PICANet team.
Regional Ethics Committee (REC) permission has 
been obtained (Wales Research Ethics Committee 5, 
17/WA/0306). This permits the ethical approach and 
consent of parents/guardians of eligible children who 
are likely to survive to 3 months following CA to enable 
telephone VABS- II assessment and identified data- linkage 
and sharing with PICANet and NET- PACK3 data.
We aim to publish the results in peer- reviewed jour-
nals and present at relevant national and international 
conferences.
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